Pfizer says FDA okays arthritis drug
Pfizer says the Food and Drug Administration approved its rheumatoid arthritis pill Xeljanz, seen as potential big seller for the company.
Pfizer Inc. says the FDA approved Xeljanz as a treatment for moderate to severe rheumatoid arthritis in patients who can't take methotrexate or haven't been helped by it. Xeljanz is intended to slow the progression of the disease. The approval comes about two weeks sooner than expected.
Xeljanz, or tofacitinib, is the first rheumatoid arthritis treatment from a new class of pain medications called JAK inhibitors. The drugs interfere with enzymes that contribute to tissue inflammation.
- Associated Press
Stories that may interest you
UCFS received $63,751 to purchase laptops, telephones and equipment to allow for tele-health checks and to pay for staff hours diverted to COVID-19 response.
The United States now has the most confirmed cases in the world and has surpassed 1,000 deaths
In what is likely to be the most optimistic statewide labor report for quite some time, the Connecticut Department of Labor reported Thursday a net job gain of 4,000 last month compared to January, and an unemployment rate below 4%.
Credit-rating agency says downgrade reflects the "meaningful earnings decline" the company is expected to experience over the next few months.